Login Register Cart 0
Generic placeholder image

Current Nutraceuticals

Editor-in-Chief

ISSN (Print): 2665-9786
ISSN (Online): 2665-9794

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

A Randomized, Placebo-controlled, Triple-blind Study to Determine the Effect of Farlong Ginseng Plus® NotoGinseng Extract on Cholesterol and Blood Pressure

Author(s): Malkanthi Evans*, Erin D. Lewis, David C. Crowley, Andy Zeng, Jing Struve and Najla Guthrie

Volume 2, Issue 4, 2021

Published on: 14 July, 2021

Article ID: e140721194774 Pages: 11

DOI: 10.2174/2665978602666210714131146

Price: $65

Open Access Journals Promotions 2
Abstract

Objective: This randomized, placebo-controlled, triple-blind study examined the efficacy of 12 weeks of Farlong NotoGinsengTM (FNG) supplementation on LDL-C and blood pressure (BP) in otherwise healthy participants (n=95) with normal to mild hypertension and hypercholesterolemia.

Methods: Lipid profile, BP, and endothelial vasodilation parameters were assessed at baseline and weeks 4, 8 and 12. Safety was assessed at screening and at end of the study. The Therapeutic Lifestyle Change (TLC) diet was followed during a 4-week run-in and throughout.

Results: Participants on FNG had a 4.33% reduction in LDL-C at week 8 (p=0.045) and a 1.80% improvement in HDL-C at week 12. Those on placebo had a non-significant 1.37% HDL-C reduction at both weeks 8 and 12. The FNG group showed a 0.94% reduction in systolic (SBP) and a 0.16% reduction in diastolic BP (DBP) at week 12. The placebo group had 0.5% and 1.24% increases in SBP and DBP, respectively. A total of 17.5% of participants supplemented with FNG had improvements in all three CVD risk factors (LDL-C, HDL-C, and SBP) compared to 5.0% of those on placebo (p=0.040). A greater proportion of participants with borderline high baseline LDL-C had reductions in their CVD risk factors (p=0.037) with FNG. However, participants in the placebo group with similar LDL-C characteristics did not have improvements in either their BP or lipid profile.

Conclusion: FNG was well-tolerated and may have a positive influence on reducing CVD risk by improving BP and lipid profile. Left unaddressed, those with CVD risk factors may progress to a more hypertensive and hypercholesterolemic state.

Keywords: Total cholesterol, LDL-cholesterol, HDL-cholesterol, blood pressure, ginseng, cardiovascular health.

Graphical Abstract

[1]
World Heart Federation. Cardiovascular diseases (CVDs) - Global facts and figures, Available from: https://www.world-heart-federation.org/resources/cardiovascular-diseases-cvds-global-facts-figures/ [Accessed September 28, 2020].
[2]
Tarride, J-E.; Lim, M.; DesMeules, M.; Luo, W.; Burke, N.; O’Reilly, D.; Bowen, J.; Goeree, R. A review of the cost of cardiovascular disease. Can. J. Cardiol., 2009, 25(6), e195-e202.
[http://dx.doi.org/10.1016/S0828-282X(09)70098-4] [PMID: 19536390]
[3]
Wilkins, E.; Wilson, L.; Wickramasinghe, K.; Bhatnagar, P.; Loeal, J.; Luengo-Fernandez, R.; Burns, R.; Rayner, M.; Townsend, N. European cardiovascular disease statistics 2017; European heart network: Brussels, 2017.
[4]
Roth, G.A.; Johnson, C.O.; Abate, K.H.; Abd-Allah, F.; Ahmed, M.; Alam, K.; Alam, T.; Alvis-Guzman, N.; Ansari, H.; Ärnlöv, J.; Atey, T.M.; Awasthi, A.; Awoke, T.; Barac, A.; Bärnighausen, T.; Bedi, N.; Bennett, D.; Bensenor, I.; Biadgilign, S.; Castañeda-Orjuela, C.; Catalá-López, F.; Davletov, K.; Dharmaratne, S.; Ding, E.L.; Dubey, M.; Faraon, E.J.A.; Farid, T.; Farvid, M.S.; Feigin, V.; Fernandes, J.; Frostad, J.; Gebru, A.; Geleijnse, J.M.; Gona, P.N.; Griswold, M.; Hailu, G.B.; Hankey, G.J.; Hassen, H.Y.; Havmoeller, R.; Hay, S.; Heckbert, S.R.; Irvine, C.M.S.; James, S.L.; Jara, D.; Kasaeian, A.; Khan, A.R.; Khera, S.; Khoja, A.T.; Khubchandani, J.; Kim, D.; Kolte, D.; Lal, D.; Larsson, A.; Linn, S.; Lotufo, P.A.; Magdy Abd El Razek, H.; Mazidi, M.; Meier, T.; Mendoza, W.; Mensah, G.A.; Meretoja, A.; Mezgebe, H.B.; Mirrakhimov, E.; Mohammed, S.; Moran, A.E.; Nguyen, G.; Nguyen, M.; Ong, K.L.; Owolabi, M.; Pletcher, M.; Pourmalek, F.; Purcell, C.A.; Qorbani, M.; Rahman, M.; Rai, R.K.; Ram, U.; Reitsma, M.B.; Renzaho, A.M.N.; Rios-Blancas, M.J.; Safiri, S.; Salomon, J.A.; Sartorius, B.; Sepanlou, S.G.; Shaikh, M.A.; Silva, D.; Stranges, S.; Tabarés-Seisdedos, R.; Tadele Atnafu, N.; Thakur, J.S.; Topor-Madry, R.; Truelsen, T.; Tuzcu, E.M.; Tyrovolas, S.; Ukwaja, K.N.; Vasankari, T.; Vlassov, V.; Vollset, S.E.; Wakayo, T.; Weintraub, R.; Wolfe, C.; Workicho, A.; Xu, G.; Yadgir, S.; Yano, Y.; Yip, P.; Yonemoto, N.; Younis, M.; Yu, C.; Zaidi, Z.; Zaki, M.E.S.; Zipkin, B.; Afshin, A.; Gakidou, E.; Lim, S.S.; Mokdad, A.H.; Naghavi, M.; Vos, T.; Murray, C.J.L. The burden of cardiovascular diseases among us states, 1990-2016. JAMA Cardiol., 2018, 3(5), 375-389.
[http://dx.doi.org/10.1001/jamacardio.2018.0385] [PMID: 29641820]
[5]
World Health Organization. The challenge of cardiovascular disease – quick statistics, 2016, 2016. Available from: https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/data-and-statistics [Accessed September 28, 2020].
[6]
Anderson, T.J.; Grégoire, J.; Pearson, G.J.; Barry, A.R.; Couture, P.; Dawes, M.; Francis, G.A.; Genest, J., Jr; Grover, S.; Gupta, M.; Hegele, R.A.; Lau, D.C.; Leiter, L.A.; Lonn, E.; Mancini, G.B.; McPherson, R.; Ngui, D.; Poirier, P.; Sievenpiper, J.L.; Stone, J.A.; Thanassoulis, G.; Ward, R. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can. J. Cardiol., 2016, 32(11), 1263-1282.
[http://dx.doi.org/10.1016/j.cjca.2016.07.510] [PMID: 27712954]
[7]
GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159), 1923-1994.
[http://dx.doi.org/10.1016/S0140-6736(18)32225-6] [PMID: 30496105]
[8]
Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L., Jr; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr; Roccella, E.J. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA, 2003, 289(19), 2560-2572.
[http://dx.doi.org/10.1001/jama.289.19.2560] [PMID: 12748199]
[9]
Schiffrin, E. L. New blood pressure cut-offs, prevalence of hypertension and control, and mood disorders: Are patients benefitting from lower cut-offs for defining hypertension? Eur. Heart J., 40(9), 739-742.
[http://dx.doi.org/10.1093/eurheartj/ehy891]
[10]
Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E., Jr; Collins, K.J.; Dennison Himmelfarb, C.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; MacLaughlin, E.J.; Muntner, P.; Ovbiagele, B.; Smith, S.C., Jr; Spencer, C.C.; Stafford, R.S.; Taler, S.J.; Thomas, R.J.; Williams, K.A., Sr; Williamson, J.D.; Wright, J.T., Jr 2017 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension, 2018, 71(6), e13-e115.
[PMID: 29133356]
[11]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) final report. Circulation, 2002, 106(25), 3143-3421.
[http://dx.doi.org/10.1161/circ.106.25.3143] [PMID: 12485966]
[12]
Eidelman, R.S.; Lamas, G.A.; Hennekens, C.H. The new national cholesterol education program guidelines: Clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch. Intern. Med., 2002, 162(18), 2033-2036.
[http://dx.doi.org/10.1001/archinte.162.18.2033] [PMID: 12374510]
[13]
Ravnskov, U.; de Lorgeril, M.; Diamond, D.M.; Hama, R.; Hamazaki, T.; Hammarskjöld, B.; Hynes, N.; Kendrick, M.; Langsjoen, P.H.; Mascitelli, L.; McCully, K.S.; Okuyama, H.; Rosch, P.J.; Schersten, T.; Sultan, S.; Sundberg, R. LDL-C does not cause cardiovascular disease: A comprehensive review of the current literature. Expert Rev. Clin. Pharmacol., 2018, 11(10), 959-970.
[http://dx.doi.org/10.1080/17512433.2018.1519391] [PMID: 30198808]
[14]
National Heart, Lung, and Blood Institute. Your tguide to lowering your cholesterol wih TLC; United States Department of Health and Human Services: United States, 2005.
[15]
Gonzalez-Compta, X. Origin of the radial artery from the axillary artery and associated hand vascular anomalies. J. Hand Surg. Am., 1991, 16(2), 293-296.
[http://dx.doi.org/10.1016/S0363-5023(10)80113-3] [PMID: 2022840]
[16]
Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002, 360(9349), 1903-1913.
[http://dx.doi.org/10.1016/S0140-6736(02)11911-8] [PMID: 12493255]
[17]
Mancia, G.; Schumacher, H.; Redon, J.; Verdecchia, P.; Schmieder, R.; Jennings, G.; Yusoff, K.; Ryden, L.; Liu, G.L.; Teo, K.; Sleight, P.; Yusuf, S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, 124(16), 1727-1736.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.008870] [PMID: 21947289]
[18]
Cooper-DeHoff, R.M.; Gong, Y.; Handberg, E.M.; Bavry, A.A.; Denardo, S.J.; Bakris, G.L.; Pepine, C.J. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA, 2010, 304(1), 61-68.
[http://dx.doi.org/10.1001/jama.2010.884] [PMID: 20606150]
[19]
Wright, J.E.; Willin, G.J.; Edwards, M.S. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 2002, 288(23), 2981-2997.
[http://dx.doi.org/10.1001/jama.288.23.2981] [PMID: 12479763]
[20]
Atasoy, S.; Johar, H.; Peters, A.; Ladwig, K.H. Association of hypertension cut-off values with 10-year cardiovascular mortality and clinical consequences: A real-world perspective from the prospective MONICA/KORA study. Eur. Heart J., 2019, 40(9), 732-738.
[http://dx.doi.org/10.1093/eurheartj/ehy694] [PMID: 30462213]
[21]
Burke, L.E.; Dunbar-Jacob, J.M.; Hill, M.N. Compliance with cardiovascular disease prevention strategies: A review of the research. Ann. Behav. Med., 1997, 19(3), 239-263.
[http://dx.doi.org/10.1007/BF02892289] [PMID: 9603699]
[22]
Bruckert, E.; Hayem, G.; Dejager, S.; Yau, C.; Bégaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc. Drugs Ther., 2005, 19(6), 403-414.
[http://dx.doi.org/10.1007/s10557-005-5686-z] [PMID: 16453090]
[23]
Kashani, A.; Phillips, C.O.; Foody, J.M.; Wang, Y.; Mangalmurti, S.; Ko, D.T.; Krumholz, H.M. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation, 2006, 114(25), 2788-2797.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.624890] [PMID: 17159064]
[24]
Wiysonge, C.S.; Bradley, H.A.; Volmink, J.; Mayosi, B.M.; Opie, L.H. Beta-blockers for hypertension. Cochrane Database Syst. Rev., 2017, 1(8), CD002003.
[PMID: 28107561]
[25]
Derosa, G.; Colletti, A.; Maffioli, P.; D’Angelo, A.; Lupi, A.; Zito, G.B.; Mureddu, G.F.; Raddino, R.; Fedele, F.; Cicero, A.F.G. Lipid-lowering nutraceuticals update on scientific evidence. J. Cardiovasc. Med. (Hagerstown), 2020, 21(11), 845-859.
[http://dx.doi.org/10.2459/JCM.0000000000000970] [PMID: 32639326]
[26]
Wang, D.; Koh, H.L.; Hong, Y.; Zhu, H.T.; Xu, M.; Zhang, Y.J.; Yang, C.R. Chemical and morphological variations of Panax notoginseng and their relationship. Phytochemistry, 2013, 93, 88-95.
[http://dx.doi.org/10.1016/j.phytochem.2013.03.007] [PMID: 23566718]
[27]
Hong, S.J.; Wan, J.B.; Zhang, Y.; Hu, G.; Lin, H.C.; Seto, S.W.; Kwan, Y.W.; Lin, Z.X.; Wang, Y.T.; Lee, S.M. Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo. Phytother. Res., 2009, 23(5), 677-686.
[http://dx.doi.org/10.1002/ptr.2705] [PMID: 19107746]
[28]
Zheng, H.; Liu, C.; Ou, Y.; Zhang, Y.; Fu, X. Total saponins of Panax notoginseng enhance VEGF and relative receptors signals and promote angiogenesis derived from rat bone marrow mesenchymal stem cells. J. Ethnopharmacol., 2013, 147(3), 595-602.
[http://dx.doi.org/10.1016/j.jep.2013.03.043] [PMID: 23545458]
[29]
Cho, Y.L.; Hur, S.M.; Kim, J.Y.; Kim, J.H.; Lee, D.K.; Choe, J.; Won, M.H.; Ha, K.S.; Jeoung, D.; Han, S.; Ryoo, S.; Lee, H.; Min, J.K.; Kwon, Y.G.; Kim, D.H.; Kim, Y.M. Specific activation of insulin- like growth factor-1 receptor by ginsenoside Rg5 promotes angiogenesis and vasorelaxation. J. Biol. Chem., 2015, 290(1), 467-477.
[http://dx.doi.org/10.1074/jbc.M114.603142] [PMID: 25391655]
[30]
Duan, L.; Xiong, X.; Hu, J.; Liu, Y.; Li, J.; Wang, J. Panax notoginseng saponins for treating coronary artery disease: A functional and mechanistic overview. Front. Pharmacol., 2017, 8, 702.
[http://dx.doi.org/10.3389/fphar.2017.00702] [PMID: 29089889]
[31]
Buettner, C.; Yeh, G.Y.; Phillips, R.S.; Mittleman, M.A.; Kaptchuk, T.J. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann. Pharmacother., 2006, 40(1), 83-95.
[http://dx.doi.org/10.1345/aph.1G216] [PMID: 16332943]
[32]
Heaney, R.P. Nutrients, endpoints, and the problem of proof. J. Nutr., 2008, 138(9), 1591-1595.
[http://dx.doi.org/10.1093/jn/138.9.1591] [PMID: 18716155]
[33]
Heaney, R.P.; Weaver, C.M.; Blumberg, J. EBN (Evidence-Based Nutrition) ver. 2.0. Nutr. Today, 2011, 46(1), 22-26.
[http://dx.doi.org/10.1097/NT.0b013e3182076fdf]
[34]
Evans, M.; Rumberger, J.A.; Azumano, I.; Napolitano, J.J.; Citrolo, D.; Kamiya, T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: A triple-blinded placebo and diet-controlled investigation. Vasc. Health Risk Manag., 2014, 10, 89-100.
[http://dx.doi.org/10.2147/VHRM.S57116] [PMID: 24600231]
[35]
Axtell, A.L.; Gomari, F.A.; Cooke, J.P. Assessing endothelial vasodilator function with the Endo-PAT 2000. J. Vis. Exp., 2010, (44), 2167.
[http://dx.doi.org/10.3791/2167] [PMID: 20972417]
[36]
D’Agostino, R.B., Sr; Vasan, R.S.; Pencina, M.J.; Wolf, P.A.; Cobain, M.; Massaro, J.M.; Kannel, W.B. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation, 2008, 117(6), 743-753.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.699579] [PMID: 18212285]
[37]
R Core Team. R: A language and environment for statistical computing; R foundation for statistical computing: Vienna, Austria, 2019.
[38]
Schwingshackl, L.; Boeing, H.; Stelmach-Mardas, M.; Gottschald, M.; Dietrich, S.; Hoffmann, G.; Chaimani, A. Dietary supplements and risk of cause-specific death, cardiovascular disease, and cancer: A systematic review and meta-analysis of primary prevention trials. Adv. Nutr., 2017, 8(1), 27-39.
[http://dx.doi.org/10.3945/an.116.013516] [PMID: 28096125]
[39]
Musa-Veloso, K.; Paulionis, L.; Pelipyagina, T.; Evans, M.; Randomized, A. A randomized, double-blind, placebo-controlled, multicentre trial of the effects of a shrimp protein hydrolysate on blood pressure. Int. J. Hypertens., 2019, 2019, 2345042.
[http://dx.doi.org/10.1155/2019/2345042] [PMID: 31467699]
[40]
Ooi, E.M.M.; Lichtenstein, A.H.; Millar, J.S.; Diffenderfer, M.R.; Lamon-Fava, S.; Rasmussen, H.; Welty, F.K.; Barrett, P.H.R.; Schaefer, E.J. Effects of therapeutic lifestyle change diets high and low in dietary fish-derived fas on lipoprotein metabolism in middle-aged and elderly subjects. J. Lipid Res., 2012, 53(9), 1958-1967.
[http://dx.doi.org/10.1194/jlr.P024315] [PMID: 22773687]
[41]
Varady, K.A.; Jones, P.J.H. Combination diet and exercise interventions for the treatment of dyslipidemia: An effective preliminary strategy to lower cholesterol levels? J. Nutr., 2005, 135(8), 1829-1835.
[http://dx.doi.org/10.1093/jn/135.8.1829] [PMID: 16046704]
[42]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. E., Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 2001, 285(19), 2486-2497.
[http://dx.doi.org/10.1001/jama.285.19.2486] [PMID: 11368702]
[43]
Vergeer, M.; Holleboom, A.G.; Kastelein, J.J.; Kuivenhoven, J.A. The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis? J. Lipid Res., 2010, 51(8), 2058-2073.
[http://dx.doi.org/10.1194/jlr.R001610] [PMID: 20371550]
[44]
Lemieux, I.; Lamarche, B.; Couillard, C.; Pascot, A.; Cantin, B.; Bergeron, J.; Dagenais, G.R.; Després, J-P. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: The Quebec Cardiovascular Study. Arch. Intern. Med., 2001, 161(22), 2685-2692.
[http://dx.doi.org/10.1001/archinte.161.22.2685] [PMID: 11732933]
[45]
Stevens, S.L.; Wood, S.; Koshiaris, C.; Law, K.; Glasziou, P.; Stevens, R.J.; McManus, R.J. Blood pressure variability and cardiovascular disease: Systematic review and meta-analysis. BMJ, 2016, 354, i4098.
[http://dx.doi.org/10.1136/bmj.i4098] [PMID: 27511067]
[46]
Hess, N.C.; Carlson, D.J.; Inder, J.D.; Jesulola, E.; McFarlane, J.R.; Smart, N.A. Clinically meaningful blood pressure reductions with low intensity isometric handgrip exercise. A randomized trial. Physiol. Res., 2016, 65(3), 461-468.
[http://dx.doi.org/10.33549/physiolres.933120] [PMID: 27070747]
[47]
Kannel, W.B. Fifty years of Framingham Study contributions to understanding hypertension. J. Hum. Hypertens., 2000, 14(2), 83-90.
[http://dx.doi.org/10.1038/sj.jhh.1000949] [PMID: 10723112]
[48]
Neaton, J.D.; Wentworth, D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch. Intern. Med., 1992, 152(1), 56-64.
[http://dx.doi.org/10.1001/archinte.1992.00400130082009] [PMID: 1728930]
[49]
Brunner, E.; White, I.; Thorogood, M.; Bristow, A.; Curle, D.; Marmot, M. Can dietary interventions change diet and cardiovascular risk factors? A meta-analysis of randomized controlled trials. Am. J. Public Health, 1997, 87(9), 1415-1422.
[http://dx.doi.org/10.2105/AJPH.87.9.1415] [PMID: 9314790]
[50]
Lechtenberg, M.; Quandt, B.; Nahrstedt, A. Quantitative determination of curcuminoids in Curcuma rhizomes and rapid differentiation of Curcuma domestica Val. and Curcuma xanthorrhiza Roxb. by capillary electrophoresis. Phytochem. Anal., 2004, 15(3), 152-158.
[http://dx.doi.org/10.1002/pca.759] [PMID: 15202598]
[51]
Kotha, R.R.; Luthria, D.L. Curcumin: Biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules, 2019, 24(16), 2930.
[http://dx.doi.org/10.3390/molecules24162930] [PMID: 31412624]
[52]
Pal, S.; Ho, S.; Gahler, R.J.; Wood, S. Effect on insulin, glucose and lipids in overweight/obese australian adults of 12 months consumption of two different fibre supplements in a randomised trial. Nutrients, 2017, 9(2), 91.
[http://dx.doi.org/10.3390/nu9020091] [PMID: 28146065]
[53]
Hobbs, C.A.; Saigo, K.; Koyanagi, M.; Hayashi, S-M. Magnesium stearate, a widely-used food additive, exhibits a lack of in vitro and in vivo genotoxic potential. Toxicol. Rep., 2017, 4, 554-559.
[http://dx.doi.org/10.1016/j.toxrep.2017.10.003] [PMID: 29090120]

Rights & Permissions Print Cite
Article Metrics
20
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy